QURE Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm

RADNOR, Pa. , Dec. 10, 2025 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) is currently investigating potential violations of the federal securities laws on behalf of investors of uniQure N.V.

PRNewsWire • Dec 10, 2025

Notice of Investigation of QURE: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm

RADNOR, Pa., Dec. 08, 2025 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) is currently investigating potential violations of the federal securities laws on behalf of investors of uniQure N.V. (NASDAQ: QURE) (“uniQure”).

GlobeNewsWire • Dec 8, 2025

Data Published in the New England Journal of Medicine Confirm the Long-term Durability and Safety of HEMGENIX® (etranacogene dezaparvovec-drlb) Over Five Years

- 94% of patients (51 of 54) remained free from the burden of continuous prophylaxis treatment through five years following a single infusion of HEMGENIX, demonstrating sustained therapeutic benefit- At year five, mean factor IX activity levels remained strong at 36.1% and HEMGENIX continued to demonstrate a favorable safety profile, reinforcing its durable efficacy- More than 75 individuals across eight countries have received HEMGENIX in real-world settings, reflecting growing global adoption KING OF PRUSSIA, Pa. , Dec. 7, 2025 /PRNewswire/ -- Global biopharma leader CSL (ASX:CSL; USOTC:CSLLY) today announced five-year (60-month) results from the pivotal Phase 3 HOPE-B study, confirming the long-term durability and safety of a one-time infusion of HEMGENIX® (etranacogene dezaparvovec-drlb) in adults living with hemophilia B.

PRNewsWire • Dec 7, 2025

UniQure Plummets, Again, As FDA Indicates It Will Reject Huntington's Gene Therapy

UniQure stock plunged, again, Thursday after the FDA said it doesn't have enough evidence for a Huntington's approval.

Investors Business Daily • Dec 4, 2025

QURE Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm

RADNOR, Pa. , Dec. 4, 2025 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) is currently investigating potential violations of the federal securities laws on behalf of investors of uniQure N.V.

PRNewsWire • Dec 4, 2025

Why uniQure Stock Is Trading Lower After FDA Meeting Update

uniQure N.V. (NASDAQ: QURE) stock is trading lower on Thursday.

Benzinga • Dec 4, 2025

uniQure Provides Regulatory Update on AMT-130 for Huntington's Disease

LEXINGTON, Mass. and AMSTERDAM, Dec. 04, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the company received final meeting minutes from the U.S. Food and Drug Administration (FDA) regarding a pre-Biologics License Application (BLA) meeting held on October 29, 2025 to discuss the application for AMT-130, an investigational gene therapy for Huntington's disease (HD).

GlobeNewsWire • Dec 4, 2025

QURE Investigation: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm

RADNOR, Pa., Dec. 02, 2025 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) is currently investigating potential violations of the federal securities laws on behalf of investors of uniQure N.V. (NASDAQ: QURE) (“uniQure”).

GlobeNewsWire • Dec 2, 2025

QURE Investigation Notification: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm

RADNOR, Pa. , Nov. 22, 2025 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) is currently investigating potential violations of the federal securities laws on behalf of investors of uniQure N.V.

PRNewsWire • Nov 22, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of uniQure N.V. - QURE

NEW YORK , Nov. 20, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  uniQure N.V. ("uniQure" or the "Company") (NASDAQ: QURE).

PRNewsWire • Nov 20, 2025